

MULTI-STATE MODEL TO ESTIMATE THE OPTIMAL DURATION OF FIRST-LINE CHEMOTHERAPY IN ADVANCED GASTRIC CANCER. DATA FROM THE NATIONAL REGISTRY AGAMENON



4CP-106

A. Arias¹, F.J. Alvarez Manceño¹, A.M. Martínez Torrón¹, A. Rodríguez Palomo¹, M.Á. Alaguero Calero¹, G. Aguado², M. Sánchez Cánovas³, N. Martínez Lago⁴, C. Herández Pérez⁵, A. Lozano-Blázquez¹.¹Hospital Universitario Central de Asturias, Hospital Pharmacy, Oviedo, Spain. ²Hospital Universitario Gregorio Marañón, Medical Oncology, Madrid, Spain. ³Hospital Universitario Morales Meseguer, Medical Oncology, Murcia, Spain. ⁴Complejo Universitario de A Coruña, Medical Oncology, A Coruña, Spain. ⁵Hospital Universitario Nuestra Señora de la Candelaria, Medical Oncology, Santa Cruz de Tenerife, Spain.

Email:
aranzazu.arias@sespa.es


Objective

Assess prognostic factors and progression-free survival (PFS) in each stratum established according to the duration of the first-line chemotherapy for patients with advanced gastric cancer (AGC)

Material and methods

The study included all patients with a histologically confirmed unresectable or AGC and first-line polychemotherapy without progression in the second evaluation of response at approximately 6 months between 2008-2018 in the 31 medical oncology services participating in the national multi-centre study AGAMENON. Patients assessed for eligibility for the AGAMENON registry (n=2789).

Results



Conclusions

In this registry of AGC, treating until progression did not impact PFS compared to maintenance or discontinuation after a predefined number of cycles.

Acknowledgements and references

We thank all the researchers of the AGAMENON registry for their contribution to this study